The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Open accessAbstract
We examined the effect of intravenously infused glucagon-like peptide 1 (GLP-1) on subjective appetite sensations after an energy-fixed breakfast, and on spontaneous energy intake at an ad libitum lunch. 20 young, healthy, normal-weight men participated in a placebo-controlled, randomized, blinded, crossover study. Infusion (GLP-1, 50 pmol/ kg.h or saline) was started simultaneously with initiation of the test meals. Visual analogue scales were used to assess appetite sensations throughout the experiment and the palatability of the test meals. Blood was sampled throughout the day for analysis of plasma hormone and substrate levels. After the energy-fixed breakfast, GLP-1 infusion enhanced satiety and fullness compared with placebo (treatment effect: P < 0.03). Furthermore, spontaneous energy intake at the ad libitum lunch was reduced by 12% by GLP-1 infusion compared with saline (P = 0.002). Plasma GLP-1, insulin, glucagon, and blood glucose profiles were affected significantly by the treatment (P < 0.002). In conclusion, the results show that GLP-1 enhanced satiety and reduced energy intake and thus may play a physiological regulatory role in controlling appetite and energy intake in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 RA increase satiety, reduce food intake and delay gastric emptying whilst they also stimulate insulin release and inhibit glucagon secretion in a glucose-dependent manner (Fig. 1) [17, 18].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Short-term studies have demonstrated that glucagon-like peptide-1 receptor agonists (GLP-1RA) induce weight loss by promoting satiety and reducing hunger16–19.”
From Exploratory analysis of eating-and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment (2022) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, non-clinical and clinical studies have demonstrated increased satiety, reduced food intake and subsequent reductions in body weight following administration of GLP-1,7, 8”
From Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults (2014) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among the two incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), the latter has been established as having therapeutic potential for reducing elevated plasma glucose (1, 2) and body weight (3), while the former has been unable to either stimulate insulin secretion (1) or lower plasma glucose effectively in type 2 diabetes (T2D) (4).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [3]
In the citing paper
“GLP-1 receptor agonists (GLP-1RA) have been shown to promote weight loss and decrease liver fat [28,29] (Figure 1).”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [29]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1975) · Journal of AOAC INTERNATIONAL · doi:10.1093/jaoac/58.5.1085 · Cited by 19,795
(1974) · Elsevier eBooks · doi:10.1016/b978-0-12-091304-6.x5001-0 · Cited by 6,755
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Self-citationTissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Self-citationInduction of intestinal epithelial proliferation by glucagon-like peptide 2.
Drucker, D. J., Erlich, P., Asa, S. L., & Brubaker, P. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7911 · Cited by 880
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Self-citationScrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Mojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724
Cited by
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
“Does peripheral GLP-1 play a physiological role as a satiating agent? Several studies have shown that infusions of GLP-1 significantly and dose dependently enhance satiety and reduce food intake in normal subjects (70, 305).”
BackgroundSelf-citationObesity and the regulation of energy balance
Spiegelman, B. M., & Flier, J. S. (2001) · Cell · doi:10.1016/s0092-8674(01)00240-9 · Cited by 2,398
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Self-citationGLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
“Relatively early acute changes in appetite, satiety, and prospective food consumption by pharmacological doses of GLP-1 were described, resulting in a corresponding reduction in caloric intake [12], thus increasing the motivation to develop compounds mimicking the physiology of GLP-1 resistant to the proteolytic inact…”
BackgroundLong-term persistence of hormonal adaptations to weight loss
Sumithran, P., Prendergast, L. A., Delbridge, E., Purcell, K., Shulkes, A., Kriketos, A., & Proietto, J. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105816 · Cited by 1,449
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Self-citationKieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
“The positive influence of the incretin hormone glucagon-like peptide-1 (GLP-1) on the metabolic disturbances of type 2 diabetes, including stimulation of insulin secretion (2, 3) and inhibition of glucagon secretion (3, 4), hepatic glucose production (5, 6), gastric emptying (7, 8), and appetite (9, 10), has provided…”
BackgroundSelf-citationThe role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
“These effects of GLP-1 are observed in lean and obese as well as diabetic humans (Flint et al., 1998; Näslund et al., 1999; Verdich et al., 2001; Zander et al., 2002).”
BackgroundO'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31773-2 · Cited by 814
Regulation of Insulin Synthesis and Secretion and Pancreatic Beta-Cell Dysfunction in Diabetes
Fu, Z., R. Gilbert, E., & Liu, D. (2013) · Current Diabetes Reviews · doi:10.2174/157339913804143225 · Cited by 732
“GLP-1—GLP-1, an incretin hormone, is secreted from small intestinal L-cells together with GIP in response to nutrient load [242, 243].”
The role of short chain fatty acids in appetite regulation and energy homeostasis
Byrne, C. S., Chambers, E. S., Morrison, D. J., & Frost, G. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.84 · Cited by 707
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693
“The effect on energy intake is consistent with previous data from non-clinical(37) and clinical studies with other GLP-1RAs,(38,39) as well as studies with native GLP-1,(3) with the reduction in energy intake correlating with reduction in body weight.(3,38,39) However, the effects with sema-”
BackgroundResultSelf-citationBjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672
Nauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., Hüfner, M., & Schmiegel, W. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8355 · Cited by 605
“This does not exclude influences on other specific functions, especially those related to the regulation of satiety (43, 44) and water intake (45).”
BackgroundSelf-citationVerdich, C., Flint, A., Gutzwiller, J.-P., Näslund, E., Beglinger, C., Hellström, P. M., Long, S. J., Morgan, L. M., Holst, J. J., & Astrup, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7877 · Cited by 600
“Furthermore, the relationship between differences in mean plasma concentration of GLP-1 and subjective sensations of hunger, prospective food consumption, and fullness were assessed using raw data from three of the studies with comparable protocols (1, 6, 10).”
BackgroundMethodSelf-citationRegulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes.
Fu, Z., Gilbert, E. R., & Liu, D. (2013) · PubMed · Cited by 600
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
“GLP-1 RAs also reduce body weight by inducing feelings of satiety and fullness and reducing feelings of hunger, thereby lowering energy intake (3,4).”
BackgroundThe Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582
Self-citationEnhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 579
Steinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578
“9 pmol·kg (1)·min (1)) reduced meal size in the absence of adverse effects in healthy-weight men (199, 255, 299, 301).”
BackgroundStoffers, D. A., Kieffer, T. J., Hussain, M. A., Drucker, D. J., Bonner-Weir, S., Habener, J. F., & Egan, J. M. (2000) · Diabetes · doi:10.2337/diabetes.49.5.741 · Cited by 576
Glucagon-like peptide-1: a potent regulator of food intake in humans
Gutzwiller, J.-P., Göke, B., Drewe, J., Hildebrand, P., Ketterer, S., Handschin, D., Winterhalder, R., Conen, D., & Beglinger, C. (1999) · Gut · doi:10.1136/gut.44.1.81 · Cited by 576
Ding, X., Saxena, N. K., Lin, S., Gupta, N., & Anania, F. A. (2006) · Hepatology · doi:10.1002/hep.21006 · Cited by 557
van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537
Self-citationCardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 530
Mattes, R. D., & Popkin, B. M. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26792 · Cited by 521
“Carbohydrate is an adequate stimulus for secretion of glucagon-like peptide-1 (GLP-1) (118– 120)—a potent incretin and satiety factor (121, 122).”
BackgroundGutzwiller, J.-P., Drewe, J., Göke, B., Schmidt, H., Rohrer, B., Lareida, J., & Beglinger, C. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.276.5.r1541 · Cited by 521
Biomarkers of satiation and satiety
de Graaf, C., Blom, W. A., Smeets, P. A., Stafleu, A., & Hendriks, H. F. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/79.6.946 · Cited by 519
“The first report of the effect of GLP-1 on human appetite comes from Flint et al (88), who showed that the exogenous intravenous infusion of GLP-1(7–36 amide) reduced the ad libitum energy intake from a test meal in 20 nonobese men by 12%.”
BackgroundGLP-1 physiology informs the pharmacotherapy of obesity
Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510
“The finding that acute GLP-1 administration rapidly promotes satiety and reduces energy intake in humans [68] has prompted extensive investigation of how GLP-1 communicates with regions of the brain critical for control of appetite and hunger.”
BackgroundMcNabney, S., & Henagan, T. (2017) · Nutrients · doi:10.3390/nu9121348 · Cited by 508
Davies, M., Pieber, T. R., Hartoft-Nielsen, M.-L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2017) · JAMA · doi:10.1001/jama.2017.14752 · Cited by 506
Biological actions and therapeutic potential of the glucagon-like peptides
Drucker, D. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.31068 · Cited by 500
Glucagon-Like Peptides: Regulators of Cell Proliferation, Differentiation, and Apoptosis
Drucker, D. J. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0306 · Cited by 483
“take after both intracerebroventricular (18) or peripheral administration (19).”
BackgroundImpact of postprandial glycaemia on health and prevention of disease
Blaak, E. E., Antoine, J. ‐., Benton, D., Björck, I., Bozzetto, L., Brouns, F., Diamant, M., Dye, L., Hulshof, T., Holst, J. J., et al. (2012) · Obesity Reviews · doi:10.1111/j.1467-789x.2012.01011.x · Cited by 477
Self-citationHavel, P. J. (2001) · Experimental Biology and Medicine · doi:10.1177/153537020122601102 · Cited by 481
Interactions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain Barrier
Kastin, A. J., Akerstrom, V., & Pan, W. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:1-2:07 · Cited by 480
“On the other hand, GLP-1 administered peripherally suppresses appetite and reduces feeding in patients with type 2 diabetes mellitus (body mass index [BMI] 29.4 kg/m 2 ) (Gutzwiller et al., 1999; Toft-Nielsen et al., 1999), in obese men (BMI 45.5 kg/m 2 ) (Naslund et al., 1999), and in healthy, normal weight men (BMI…”
BackgroundInfluentialEnergy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
Näslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J., Holst, J., Rössner, S., & Hellström, P. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800818 · Cited by 468
Self-citationExendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers
Edwards, C. M. B., Stanley, S. A., Davis, R., Brynes, A. E., Frost, G. S., Seal, L. J., Ghatei, M. A., & Bloom, S. R. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.1.e155 · Cited by 464
“A number of recent studies have assessed the effects of GLP-1 infusion on caloric intake (11, 17, 18, 23, 25, 41).”
BackgroundCani, P. D., Dewever, C., & Delzenne, N. M. (2004) · British Journal of Nutrition · doi:10.1079/bjn20041225 · Cited by 447
“There are several papers showing that peripheral injection of GLP-1 (7-36) amide decreases food intake and consequently body weight in rats and human subjects (Flint et al. 1998; Naslund et al. 1999; Meier et al. 2002; Zander et al. 2002).”
BackgroundIncretins, insulin secretion and Type 2 diabetes mellitus
Vilsbøll, T., & Holst, J. J. (2004) · Diabetologia · doi:10.1007/s00125-004-1342-6 · Cited by 444
“This has been shown in both normal subjects, obese subjects and subjects with Type 2 diabetes mellitus [99, 100, 101].”
BackgroundSelf-citationGlucagon-Like Peptide 1 Induces Natriuresis in Healthy Subjects and in Insulin-Resistant Obese Men
Gutzwiller, J.-P., Tschopp, S., Bock, A., Zehnder, C. E., Huber, A. R., Kreyenbuehl, M., Gutmann, H., Drewe, J., Henzen, C., Goeke, B., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031403 · Cited by 442
Verdich, C., Toubro, S., Buemann, B., Lysgård Madsen, J., Juul Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801655 · Cited by 434
Self-citationNauck, M. A., Duran, S., Kim, D., Johns, D., Northrup, J., Festa, A., Brodows, R., & Trautmann, M. (2007) · Diabetologia · doi:10.1007/s00125-006-0510-2 · Cited by 437
“In addition, both GLP-1 and exenatide have been shown to enhance beta cell mass in animal models [6, 7].”
BackgroundInfluentialSubcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects
Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2390 · Cited by 435
Medicinal strategies in the treatment of obesity
Bray, G. A., & Tartaglia, L. A. (2000) · Nature · doi:10.1038/35007544 · Cited by 432
Degn, K. B., Juhl, C. B., Sturis, J., Jakobsen, G., Brock, B., Chandramouli, V., Rungby, J., Landau, B. R., & Schmitz, O. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1187 · Cited by 427
“Furthermore, it delays gastric emptying (9,11) and may even be a satiety factor.”
BackgroundGLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans
van Bloemendaal, L., IJzerman, R. G., ten Kulve, J. S., Barkhof, F., Konrad, R. J., Drent, M. L., Veltman, D. J., & Diamant, M. (2014) · Diabetes · doi:10.2337/db14-0849 · Cited by 427
“In contrast to previous studies (50), we found no statistically significant effects of GLP-1 receptor activation on scores of hunger, fullness, appetite, prospective food consumption, and desire to eat.”
ResultHow May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial.
Rodbard, H. W., Lingvay, I., Reed, J., de la Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P.-L., Wijayasinghe, N., & Norwood, P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00070 · Cited by 412
Christiansen, C. B., Gabe, M. B. N., Svendsen, B., Dragsted, L. O., Rosenkilde, M. M., & Holst, J. J. (2018) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00346.2017 · Cited by 401
“Through secretion of GLP-1 and PYY, SCFAs may indirectly affect host metabolism by increasing satiety and decreasing gastric emptying and gut motility (25, 47).”
BackgroundSelf-citationGraaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
“Indeed, infusion of GLP-1 into normal human subjects significantly enhances satiety and decreases food intake (Flint et al., 1998).”
BackgroundNauck, M. A., & D‘Alessio, D. A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01604-7 · Cited by 407
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
“(exendin [9-39]) and, more recently, a GIP receptor agonist (GIP [3-30] NH2) and, hopefully, longer-acting GIP receptor agonists for human use will be helpful tools to”
BackgroundBaggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2492 · Cited by 386
“GLP-1 also produces anorectic effects, and short-term infusion of GLP-1 is associated with diminished appetite and reduced energy consumption in normal, obese, and diabetic human subjects (3).”
BackgroundFlint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801627 · Cited by 384
Self-citationOligofructose Promotes Satiety in Rats Fed a High‐Fat Diet: Involvement of Glucagon‐Like Peptide‐1
Cani, P. D., Neyrinck, A. M., Maton, N., & Delzenne, N. M. (2005) · Obesity Research · doi:10.1038/oby.2005.117 · Cited by 382
Oligofructose promotes satiety in healthy human: a pilot study
Cani, P. D., Joly, E., Horsmans, Y., & Delzenne, N. M. (2006) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1602350 · Cited by 382
“Consistent with these studies, intravenous infusion of GLP-1 in humans enhances satiety and decreases energy intake during the period of infusion (Flint et al., 1998, 2001).”
BackgroundResultDIETARY FIBER AND BODY-WEIGHT REGULATION
Pereira, M. A., & Ludwig, D. S. (2001) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(05)70351-5 · Cited by 372
Baggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.063 · Cited by 372
Meier, J. J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030049 · Cited by 369
Self-citationGough, S. C. L., Bode, B., Woo, V., Rodbard, H. W., Linjawi, S., Poulsen, P., Damgaard, L. H., & Buse, J. B. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70174-3 · Cited by 366
Raben, A., Agerholm-Larsen, L., Flint, A., Holst, J. J., & Astrup, A. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/77.1.91 · Cited by 365
“Although both insulin and GLP-1 were increased after the carbohydrate meal, hunger and energy intake were not lower after this diet than after the other meals, as might have been expected (57, 58).”
BackgroundResultSelf-citationEffects of exercise on gut peptides, energy intake and appetite
Martins, C., Morgan, L. M., Bloom, S. R., & Robertson, M. D. (2007) · Journal of Endocrinology · doi:10.1677/joe-06-0030 · Cited by 356
“…in the plasma levels of these gut peptides, together with a significant suppression in hunger scores (compared with infusion of saline) have been reported in studies where these hormones were infused to normal-weight healthy volunteers (Flint et al. 1998, Batterham et al. 2003, Degen et al. 2005).”
ResultSatiation, satiety and their effects on eating behaviour
Benelam, B. (2009) · Nutrition Bulletin · doi:10.1111/j.1467-3010.2009.01753.x · Cited by 340
Cancer anorexia-cachexia syndrome: are neuropeptides the key?
Inui, A. (1999) · PubMed · Cited by 342
Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders
GORRELL, M. D. (2005) · Clinical Science · doi:10.1042/cs20040302 · Cited by 334
Current and Potential Drugs for Treatment of Obesity
Bray, G. A., & Greenway, F. L. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0383 · Cited by 331
What is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
“1) [17, 18].”
Breton, J., Tennoune, N., Lucas, N., Francois, M., Legrand, R., Jacquemot, J., Goichon, A., Guérin, C., Peltier, J., Pestel-Caron, M., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.10.017 · Cited by 321
“The obtained c-Fos pattern resembles that of a satietogenic response during food ingestion (Johnstone et al., 2006) or induced by satiety hormones such as PYY or pancreatic polypeptide (Batterham et al., 2002; Blevins et al., 2008; Challis et al., 2004; Lin et al., 2009).”
InfluentialEffects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
van Bloemendaal, L., ten Kulve, J. S., la Fleur, S. E., Ijzerman, R. G., & Diamant, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0414 · Cited by 312
“Also in humans, GLP-1 was shown to reduce food intake, appetite, and hunger and to promote fullness and satiety (Flint et al. 1998, 2001, Naslund et al. 1998, Gutzwiller et al. 1999, Verdich et al. 2001).”
Jendle, J., Nauck, M. A., Matthews, D. R., Frid, A., Hermansen, K., Düring, M., Zdravkovic, M., Strauss, B. J., Garber, A. J., & Groups, O. B. O. T. L. A. L. S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01158.x · Cited by 312
Madsbad, S., Schmitz, O., Ranstam, J., Jakobsen, G., Matthews, D. R., & on behalf of the NN2211-1310 International Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1335 · Cited by 312
The defence of body weight: a physiological basis for weight regain after weight loss
Sumithran, P., & Proietto, J. (2013) · Clinical Science · doi:10.1042/cs20120223 · Cited by 310
Näslund, E., Gutniak, M., Skogar, S., Rössner, S., & Hellström, P. M. (1998) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/68.3.525 · Cited by 307
Talsania, T., Anini, Y., Siu, S., Drucker, D. J., & Brubaker, P. L. (2005) · Endocrinology · doi:10.1210/en.2005-0473 · Cited by 306
Meeran, K., O’Shea, D., Edwards, C. M. B., Turton, M. D., Heath, M. M., Gunn, I., Abusnana, S., Rossi, M., Small, C. J., Goldstone, A. P., et al. (1999) · Endocrinology · doi:10.1210/endo.140.1.6421 · Cited by 303
Exendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats
Szayna, M. (2000) · Endocrinology · doi:10.1210/en.141.6.1936 · Cited by 303
Effects of Resistant Starch, A Non‐digestible Fermentable Fiber, on Reducing Body Fat
Keenan, M. J., Zhou, J., McCutcheon, K. L., Raggio, A. M., Bateman, H. G., Todd, E., Jones, C. K., Tulley, R. T., Melton, S., Martin, R. J., et al. (2006) · Obesity · doi:10.1038/oby.2006.176 · Cited by 302
“This result may indicate that consumption of fermentable RS may have a beneficial role in long-term energy balance (18,19) because administration of PYY or GLP-1 has been shown to reduce energy intake (20,21).”
BackgroundRobinson, L. E., Holt, T. A., Rees, K., Randeva, H. S., & O'Hare, J. P. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-001986 · Cited by 296
“[2] The mechanisms producing weight loss have been extensively investigated, and involve improved satiety and reduced calorie ingestion both through effects on the central nervous system and through delayed gastric emptying.[3-6] Those leading to reduced blood pressure are less adequately understood, but this effect h…”
BackgroundUnderwood, C. R., Garibay, P., Knudsen, L. B., Hastrup, S., Peters, G. H., Rudolph, R., & Reedtz-Runge, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.033829 · Cited by 295
Nauck, M. A. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.002 · Cited by 295
The structure and function of the glucagon‐like peptide‐1 receptor and its ligands
Donnelly, D. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01687.x · Cited by 292
“, 1997), promoting satiety (Turton et al., 1996; Flint et al., 1998) and increasing peripheral glucose disposal (D’Alessio et al.”
BackgroundTreatment of type 2 diabetes: challenges, hopes, and anticipated successes
Nauck, M. A., Wefers, J., & Meier, J. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00113-3 · Cited by 289
Glucagon-like peptide 1(GLP-1) in biology and pathology
Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288
“Furthermore, an increased feeling of fullness associated with reduced appetite has uniformly been reported after short-term administration of the peptide [58,125,127].”
BackgroundInfluentialGLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans
Näslund, E., Bogefors, J., Skogar, S., Grybäck, P., Jacobsson, H., Holst, J. J., & Hellström, P. M. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.277.3.r910 · Cited by 284
“In addition, GLP-1 has been shown to inhibit food intake on intracerebroventricular injection in animal models (33) and after intravenous infusion in normalweight (9) and obese humans (24).”
BackgroundSelf-citationNauck, M., Weinstock, R. S., Umpierrez, G. E., Guerci, B., Skrivanek, Z., & Milicevic, Z. (2014) · Diabetes Care · doi:10.2337/dc13-2761 · Cited by 284
“The mechanisms of weight loss with GLP-1 receptor agonists are probably related to their actions in the GI and/or central nervous system (33,34).”
BackgroundRolin, B., Larsen, M. O., Gotfredsen, C. F., Deacon, C. F., Carr, R. D., Wilken, M., & Knudsen, L. B. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00030.2002 · Cited by 281
Breakfast Frequency and Quality in the Etiology of Adult Obesity and Chronic Diseases
Timlin, M. T., & Pereira, M. A. (2007) · Nutrition Reviews · doi:10.1301/nr.2007.jun.268-281 · Cited by 279
Inter-organ cross-talk in metabolic syndrome
Priest, C., & Tontonoz, P. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0145-5 · Cited by 279
Freeland, K. R., & Wolever, T. M. S. (2010) · British Journal of Nutrition · doi:10.1017/s0007114509991863 · Cited by 275
Dose-dependent satiating effect of whey relative to casein or soy
Veldhorst, M. A. B., Nieuwenhuizen, A. G., Hochstenbach-Waelen, A., van Vught, A. J. A. H., Westerterp, K. R., Engelen, M. P. K. J., Brummer, R.-J. M., Deutz, N. E. P., & Westerterp-Plantenga, M. S. (2009) · Physiology & Behavior · doi:10.1016/j.physbeh.2009.01.004 · Cited by 270
Obesity – is it a genetic disorder?
Loos, R. J. F., & Bouchard, C. (2003) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01242.x · Cited by 270
Metabolic activities and probiotic potential of bifidobacteria
Russell, D. A., Ross, R. P., Fitzgerald, G. F., & Stanton, C. (2011) · International Journal of Food Microbiology · doi:10.1016/j.ijfoodmicro.2011.06.003 · Cited by 267
Metadata
- Authors
- Flint, A., Raben, A., Astrup, A., & Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Venue
- Journal of Clinical Investigation
- Published
- 1998-02-01
- Volume
- 101
- Issue
- 3
- Pages
- 515-520
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC508592
- OpenAlex
- W1975756049
- Cited by
- 1,402
- References
- 40
- Citations by year
- 2026: 37 · 2025: 55 · 2024: 62 · 2023: 33 · 2022: 55 · 2021: 53 · 2020: 49 · 2019: 44 · 2018: 52 · 2017: 49 · 2016: 54 · 2015: 59 · 2014: 64 · 2013: 74 · 2012: 72
- FWCI
- 9.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Sundhed og Sygdom, Det Frie Forskningsråd
- Medical Research Council
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- glucagon-like peptide-1, satiety, appetite, energy intake, insulin, glucagon, blood glucose, appetite regulation, intravenous infusion
- MeSH terms
- Adult, Appetite, Appetite Depressants, Appetite Regulation, Blood Glucose, Energy Intake, Glucagon, Humans, Insulin, Male, Pain Measurement, Peptide Fragments, Protein Precursors, Satiation, Cross-Over Studies, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.